Will Osiris's 'overwhelming' data shove Shire's Dermagraft in the mire?
This article was originally published in Scrip
Executive Summary
Shares in Osiris Therapeutics shot up 125% in morning trading on 13 August after the firm announced it has stopped a study of its Grafix cellular wound care product in diabetic foot ulcer because of "overwhelming efficacy." Its stock was trading at $24.01 during the day, up from a closing price on $10.66 on 12 August.